NVP-AUY922 is an experimental drug candidate for the treatment of cancer. It was discovered through a collaboration between The Institute of Cancer Research and the pharmaceutical company Vernalis and licensed to Novartis. It is currently in Phase II clinical trials. NVP-AUY922 is an inhibitor of heat shock protein 90 (Hsp90), which is a chaperone protein that plays a role in the modification of a variety of proteins that have been implicated in oncogenesis. NVP-AUY922 has shown promising activity in preclinical testing against several different tumor types.
China![CAS No:747412-49-3 (5Z)-N-ethyl-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,<br />4-dien-1-ylidene)-4-[4-(morpholin-4-ylmethyl)phenyl]-2H-1,<br />2-oxazole-3-carboxamide](/structure/cas-747/747412-49-3.png)